Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)		1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
		Dec. 31, 2022	May 31, 2018	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Feb. 28, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current		$ 1,733,000		$ 3,670,000		$ 3,670,000		$ 1,733,000
Deferred revenue - non-current		37,684,000		69,469,000		69,469,000		37,684,000
Total revenue from UT				51,253,000	$ 32,825,000	140,490,000	$ 63,711,000
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				13,108,000	10,346,000	35,705,000	18,380,000
AFREZZA product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				17,927,000	16,259,000	53,834,000	38,807,000
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				33,289,000	16,529,000	86,546,000	24,268,000
United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for development of alternative manufacturing processes		2,300,000
United Therapeutics Corporation | Commercialization and Continuous Improvement Activities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for capital improvements		39,500,000
Thirona Bio, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funded amount						200,000
Minimum amount to expended									$ 1,100,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows	[1]	722,300,000						722,300,000
Deferred revenue		37,900,000		71,700,000		71,700,000		37,900,000
Deferred revenue - current		1,600,000		3,500,000		3,500,000		1,600,000
Deferred revenue - non-current		36,300,000		68,200,000		68,200,000		36,300,000
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		722,300,000						722,300,000
Allocated transaction price		220,800,000
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Transaction Price For The Contractual Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		120,000,000						120,000,000
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		$ 602,300,000						602,300,000
Commercial Supply Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				12,800,000	9,916,000	34,897,000	15,795,000
Supply and Distribution Agreement | AFREZZA product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						0		$ 0
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue				1,400,000		1,400,000
Deferred revenue - current				100,000		100,000
Deferred revenue - non-current				1,300,000		1,300,000
Marketing and distribution agreement date			2018-05
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				$ 37,000	$ 37,000	$ 110,000	$ 110,000

[1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.